SavedAdd your journal

Journals / Turkish Journal of Obstetrics and Gynecology / 2019 / Cilt: 16 - Sayı: 1

Cost-effectiveness of GnRH antagonist implementation on hCG injection day

hCG gününde GnRh antagonist yapmanın maliyet etkinliği

Çağrı GÜLÜMSER
Davut GÜVEN
Ayşe Zehra ÖZDEMİR
Bülent AYAS
Aysun TÜRKMEN
Pages
29–34
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The stimulation outcomes of patients and cost-effectiveness of the regimens were compared.Results: There was a significant difference between the groups in terms of number of cryopreserved embryos, mature/immature oocyte ratio, and embryo transfer cancellations (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare the outcomes of antagonist stimulation protocols and to compare the cost effectiveness.Materials and Methods: Between 2011 and December 2017, a total of 354 women who underwent intracytoplasmic sperm injection and controlled ovarian stimulation with antagonist protocols were enrolled in the study.
📊
Key Findings & Data:The antagonist implementation on the day of human chorionic gonadotropin (hCG) was continued for 194 of women, whereas the antagonist was stopped 36 hours before in 160 women.
💡
Conclusion & Impact:The stimulation outcomes of patients and cost-effectiveness of the regimens were compared.Results: There was a significant difference between the groups in terms of number of cryopreserved embryos, mature/immature oocyte ratio, and embryo transfer cancellations (p
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To compare the outcomes of antagonist stimulation protocols and to compare the cost effectiveness.Materials and Methods: Between 2011 and December 2017, a total of 354 women who underwent intracytoplasmic sperm injection and controlled ovarian stimulation with antagonist protocols were enrolled in the study. The antagonist implementation on the day of human chorionic gonadotropin (hCG) was continued for 194 of women, whereas the antagonist was stopped 36 hours before in 160 women. The stimulation outcomes of patients and cost-effectiveness of the regimens were compared.Results: There was a significant difference between the groups in terms of number of cryopreserved embryos, mature/immature oocyte ratio, and embryo transfer cancellations (p

Özet

Amaç: Antagonist stimülasyon protokollerinin maliyet etkinliğini ve stimülasyon sonuçlarını kıyaslamaktır.Gereç ve Yöntemler: Çalışmaya 2011-2017 yılları arasında intrastoplazmik sperm enjeksiyonu yapılan 354 hasta alınmıştır. Hastaların tamamında antagonist protokolle stimülasyon yapılmıştır. Hastaların 194 tanesinde insan koryonik gonadotropin (hCG) gününde antagonist yapılmaya devam edilmiştir. Yüz altmış hastada ise antagonist hCG gününden 36 saat önce kesilmiştir. Hastaların stimülasyon sonuçları ve iki farklı rejimin maliyet etkinliği karşılaştırılmıştır.Bulgular: Gruplar arasında dondurulmuş embryo sayısı, matür/immatür oosit oranı ve transfer iptali açısından anlamlı farklılık bulunmuştur (p

🔖

Cite This Article

GÜLÜMSER, Ç., GÜVEN, D., ÖZDEMİR, A. Z., AYAS, B., TÜRKMEN, A. (2022). Cost-effectiveness of GnRH antagonist implementation on hCG injection day. Turkish Journal of Obstetrics and Gynecology, Cilt: 16 - Sayı: 1, 29–34. https://ajindex.com/articles/613006

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kolibianakis EM, Tarlatzis B, Devroey P. GnRH antagonists in IVF. Reprod Biomed Online [Internet] 2005;10:705-12. Available from:
  2. Copperman AB, Benadiva C. Optimal usage of the GnRH antagonists: A review of the literature. Reprod Biol Endocrinol 2013;11:1-13
  3. Gordon K, Hodgen GD. GnRH agonists and antagonists in assisted reproduction. Baillieres Clin Obstet Gynaecol 1992;6:247-65
  4. Olivennes F, Belaisch-Allart J, Emperaire JC, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LHRH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000;73:314-20
  5. Johnston-MacAnanny EB, DiLuigi AJ, Engmann LL, Maier DB, Benadiva CA, Nulsen JC. Selection of first in vitro fertilization cycle stimulation protocol for good prognosis patients: gonadotropin releasing hormone antagonist versus agonist protocols. J Reprod Med [Internet] 2011;56:12-6. Available from: http://www.ncbi.nlm. nih.gov/pubmed/21366121
  6. Al-Inany H, Youssef M. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Database Syst Rev [Internet] 2011;CD001750. Available from: http://www.ncbi.nlm. nih.gov/pubmed/21563131%5Cnhttp://onlinelibrary.wiley.com/ doi/10.1002/14651858.CD001750.pub3/pdf/standard 7. Chang HJ, Lee JR, Jee BC, Suh CS, Lee WD, Kim SH. Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multipledose protocol: A randomized controlled study. Clin Exp Reprod Med 2013;40:83-9
  7. Chang HJ, Lee JR, Jee BC, Suh CS, Kim SH. Cessation of gonadotropinreleasing hormone antagonist on triggering day: an alternative method for flexible multiple-dose protocol. Send to J Korean Med Sci 2009;24:262-8
  8. Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimülation. Hum Reprod 1996;11:917-9
  9. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333-40
  10. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: A systematic review and meta-analysis. Vol. 12, Human Reprod Update 2006;12 p. 159-68
  11. Prapas Y, Ravanos K, Petousis S, Panagiotidis Y, Papatheodorou A, Margioula-siarkou C, et al. GnRH antagonist administered tw